---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-032121"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2024-03-08T23:59:59+00:00"
generated_at: "2026-06-05T00:49:19.272348+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics Q4 net loss $24.5M; cash $467.3M; Phase 2a data due Q2 2024

## Summary
- Net loss for Q4 2023 was $24.5M ($89.6M full year); compared to $11.9M in Q4 2022.
- Cash and equivalents $467.3M at year-end; expected to fund operations through 2026.
- Topline GSBR-1290 Phase 2a obesity data (12-week) expected latter half of Q2 2024.
- Phase 2b obesity study of GSBR-1290 planned to start Q4 2024.
- R&D expenses $20.0M in Q4 2023 ($70.1M full year), up from $8.4M in Q4 2022.

## SEC filing metadata
- accession: 0001104659-24-032121
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2024-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/0001104659-24-032121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/tm248154d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-032121
- JSON: https://secwatch.observer/filing/0001104659-24-032121.json
- Plain text: https://secwatch.observer/filing/0001104659-24-032121.txt

## Key facts
- Earnings Releases
  Structure Therapeutics Inc. reported the fourth quarter of 2023 results: net income Net loss for the fourth quarter of 2023 totaled $24.5.
  - Period: the fourth quarter of 2023
  - Net income: Net loss for the fourth quarter of 2023 totaled $24.5
  - Result: reported results
  source text: Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/0001104659-24-032121-index.htm
- Earnings Releases
  Structure Therapeutics Inc. reported the year ended December 31, 2023 results: net income For the year ended December 31, 2023, net loss totaled $89.6 million.
  - Period: the year ended December 31, 2023
  - Net income: For the year ended December 31, 2023, net loss totaled $89.6 million
  - Result: reported results
  source text: For the year ended December 31, 2023, net loss totaled $89.6 million, with non-cash stock-based compensation expense of $8.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/0001104659-24-032121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.